Skip to main content

Articles

Page 11 of 11

  1. Intermediate uveitis (IU) is generally believed to be autoimmune in nature requiring systemic corticosteroid and immunomodulatory therapy. This belief stems from the published reports from the developed countr...

    Authors: Swapnil Parchand, Manjari Tandan, Vishali Gupta and Amod Gupta
    Citation: Journal of Ophthalmic Inflammation and Infection 2011 1:20
  2. Secondary glaucoma is a difficult and frequent complication of uveitis. The aim of this study is to describe the results of surgery in uveitic glaucoma and to identify situations linked to a high risk of failu...

    Authors: Ester Carreño, Sonia Villarón, Alejandro Portero, José M. Herreras, José A. Maquet and Margarita Calonge
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:12
  3. Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive...

    Authors: Efrem D. Mandelcorn, Alan G. Palestine, Sandor Dubovy and Janet L. Davis
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:13
  4. The aim of this report is to present a previously unreported causative organism associated with brown-pigmented hypopyon in a patient with endophthalmitis.

    Authors: Adam Hauch, Dean Eliott, Narsing A. Rao, Daniel V. Vasconcelos-Santos, Thomas O’Hearn and Amani A. Fawzi
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:8
  5. Uveitis comprises an extensive array of intraocular inflammatory diseases and often results in irreversible visual loss. Experimental autoimmune uveitis (EAU) is an animal model used to study human uveitis. Bo...

    Authors: Angeline M. Nguyen and Narsing A. Rao
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:7

Annual Journal Metrics

  • 2022 Citation Impact
    2.9 - 2-year Impact Factor
    2.9 - 5-year Impact Factor
    1.381 - SNIP (Source Normalized Impact per Paper)
    0.607 - SJR (SCImago Journal Rank)

    2022 Speed
    9 days submission to first editorial decision for all manuscripts (Median)
    125 days submission to accept (Median)

    2022 Usage
    250,642 downloads
    354 Altmetric mentions